Overview PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Status: Completed Trial end date: 2016-02-01 Target enrollment: Participant gender: Summary The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy. Phase: Phase 4 Details Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.